Ipsen forges $1bn alliance with Exicure on neurodegenerative diseasesIpsen’s new chief executive David Loew pledged to ramp up spending on the company’s pipeline when he took Share XIpsen forges $1bn alliance with Exicure on neurodegenerative diseaseshttps://pharmaphorum.com/news/ipsen-forges-1bn-alliance-with-exicure-on-neurodegenerative-diseases/
Allergan bolsters aesthetics pipeline with Exicure hair loss dealAllergan hasn’t pressed pause on business development in the build-up to its $63 billion buyout by AbbVie, and Share XAllergan bolsters aesthetics pipeline with Exicure hair loss dealhttps://pharmaphorum.com/news/allergan-bolsters-aesthetics-unit-with-exicure-hair-loss-deal/
Exicure lists on Nasdaq, raising $55m for cancer, neurology pushUS biotech Exicure has raised $55 million in a public offering that has seen its shares elevated from Share XExicure lists on Nasdaq, raising $55m for cancer, neurology pushhttps://pharmaphorum.com/news/exicure-lists-on-nasdaq-raising-55m-for-cancer-neurology-push/
